September 30, 2008 - Co-led by Clarus Ventures and SV Life Sciences,the Financing will Advance Preclinical and Clinical Programs - Link Medicine Corporation, a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, announced that it has obtained $40 million of Series C equity financing to help move its lead preclinical programs into human clinical testing. The round was funded by two leading biotechnology investors – Clarus Ventures and SV Life Sciences. Link Medicine, founded in March 2005, is focused on developing the first disease-modifying therapies for the treatment of several neurodegenerative diseases – including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis (ALS). The company is pursuing innovative approaches to target a common feature of these disorders - the buildup in nerve cells of incorrectly folded, aggregated and ultimately neurotoxic proteins... Link Medicine Corporation's Press Release -
